T 1825/21 of 13.03.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T182521.20230313
- Date of decision
- 13 March 2023
- Case number
- T 1825/21
- Petition for review of
- -
- Application number
- 16167355.3
- IPC class
- C07D 401/12A61K 31/506A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE
- Applicant name
- NOVARTIS AG
- Opponent name
- Generics (UK) Ltd
Teva Pharmaceutical Industries Ltd - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Inventive step
- Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The oppositions are rejected.